Navigation Links
Generex Awarded a New Patent in Canada for its Proprietary Buccal Drug Delivery System
Date:9/28/2010

WORCESTER, Mass., Sept. 28 /PRNewswire/ -- Generex Biotechnology Corporation (Nasdaq: GNBT, www.generex.com), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has been awarded a new patent in Canada.

The Canadian Intellectual Property Office granted Canadian Patent No. 2,401,942, a patent titled "Pharmaceutical Compositions for Buccal and Pulmonary Application".

This new patent increases the number of issued patents related to the Company's buccal drug delivery platform technologies to 161.  A total of 102 patent applications remain pending.

"We are pleased that we continue to establish the inventiveness of the Company's buccal delivery system as there has been relatively little progress over the years in reaching the target of safe and effective oral formulations for macromolecules, including peptides and proteins", stated Rose C. Perri, the Company's Chief Operating Officer.  "We are pleased that we continue to receive patents from key markets within which our delivery system can be commercialized with a pipeline of viable applications that will open up other marketplaces for the Company".  

About Generex Biotechnology Corporation

Generex is engaged in the research, development and commercialization of drug delivery systems and technologies.  Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs).  The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist™ device.  The Company's flagship product, oral insulin (Generex Oral-lyn™), which has been launched in India, Lebanon, Algeria, and Ecuador for the treatment of subjects with Type-1 and Type-2 diabetes, is in Phase III clinical trials at several sites around the world.  Antigen Express, Inc. is a wholly owned subsidiary of Generex.  The core platform technologies of Antigen Express comprise immunotherapeutics for the treatment of malignant, infectious, allergic, and autoimmune diseases.  For more information, visit the Generex website at www.generex.com or the Antigen Express website at www.antigenexpress.com.

Safe Harbor Statement

This release and oral statements made from time to time by Generex representatives in respect of the same subject matter may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements can be identified by introductory words such as "expects," "plans," "intends," "believes," "will," "estimates," "forecasts," "projects," or words of similar meaning, and by the fact that they do not relate strictly to historical or current facts.  Forward-looking statements frequently are used in discussing potential product applications, potential collaborations, product development activities, clinical studies, regulatory submissions and approvals, and similar operating matters. Many factors may cause actual results to differ from forward-looking statements, including inaccurate assumptions and a broad variety of risks and uncertainties, some of which are known and others of which are not.  Known risks and uncertainties include those identified from time to time in the reports filed by Generex with the Securities and Exchange Commission, which should be considered together with any forward-looking statement.  No forward-looking statement is a guarantee of future results or events, and one should avoid placing undue reliance on such statements.  Generex undertakes no obligation to update publicly any forward-looking statements, whether as a result of new information, future events or otherwise.  Generex cannot be sure when or if it will be permitted by regulatory agencies to undertake additional clinical trials or to commence any particular phase of clinical trials.  Because of this, statements regarding the expected timing of clinical trials cannot be regarded as actual predictions of when Generex will obtain regulatory approval for any "phase" of clinical trials.  Generex claims the protection of the safe harbor for forward-looking statements that is contained in the Private Securities Litigation Reform Act.


'/>"/>
SOURCE Generex Biotechnology Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Generex Presents Abstract at EASD Annual Meeting
2. Generex Announces Sales Agreement with Elias Shaker & Company
3. Generex Announces Approval of Adjournment Proposal and Adjourned Special Meeting Date
4. Generex Announces Presentations of Novel Vaccine Strategies
5. Generex Announces Distribution Agreement for Generex Oral-lyn™ in Chile
6. Generex Biotechnology Corporation Initiation Coverage Review Issued By Scimitar Equity, LLC
7. Microfluidic Systems (MFSI) is Awarded Four New Patents in the Field of Automated Biological Sample Processing and Detection.
8. WuXi PharmaTech Awarded GLP Certificate from OECD for Suzhou Toxicology Facility
9. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
10. Sysmex America Awarded National Novation GPO Contract for Automated Urinalysis
11. Pfenex Inc. Awarded Contract With the United States Federal Government Potentially Totaling Up to $18.8 Million to Develop a Robust Pfenex Expression Technology Based Process for the Production of Bulk Recombinant Protective Antigen (rPA) From Anthr
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2019)... ... December 05, 2019 , ... ... off-the-record collaboration and dialogue, today announces key issues to be discussed at its ... Four Seasons Hotel in San Francisco. , Kicking off ...
(Date:12/4/2019)... ... December 04, 2019 , ... The Harm Reduction Institute (HRI) as a ... drug and alcohol rehab center and non-profit Intensive outpatient after care (IOP) ... outreach, trained, and distributed Naloxone amongst members of the own community in Orange County, ...
(Date:12/4/2019)... ... December 04, 2019 , ... ... delivering solutions designed for improved financial, operational and clinical health for our ... Fellow designation from the American College of Healthcare Executives (ACHE). , ACHE ...
Breaking Medicine Technology:
(Date:12/2/2019)... ... December 02, 2019 , ... More than $400 million dollars ... December 31. While many people spend their tax-free funds throughout the year, many more ... Year’s Eve. In an effort to help account holders use -- not lose -- ...
(Date:11/30/2019)... Texas (PRWEB) , ... November 28, 2019 , ... As ... may be the last such holiday for one of their loved ones. For those ... them to be home for the holiday season. , Spending their final months at ...
(Date:11/30/2019)... ... November 29, 2019 , ... This Black Friday through Cyber ... family of brands—Gorilla Grow Tent, Kind LED Grow Lights, Lotus Nutrients, and SuperCloset. ... 5’x5’ Gorilla Grow Tent . The best-selling grow tent in Gorilla’s collection, the ...
(Date:11/27/2019)... (PRWEB) , ... November 27, 2019 , ... AltMed ... (source: OMMU), has announced the grand opening of its newest MÜV™ Medical ... Florida Avenue in Lakeland. , AltMed’s eleventh MÜV Dispensary in Florida, is located on ...
(Date:11/23/2019)... ... November 22, 2019 , ... HolistaPet, a leading CBD manufacturer for pets, today ... for Horses and CBD Pellets for Horses . The line of horse ... of CBD to horses. , “We are truly excited to bring the amazing benefits ...
Breaking Medicine News(10 mins):